NTII Neurobiological Technologies (MM)

EMERYVILLE, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII) today announced the appointment of William A. Fletcher to the Board of Directors. William Fletcher was President & CEO of Teva's North American activities from 1985 until the end of 2004, when he became Chairman - North America. Teva, one of Israel's largest industrial companies, holds the leading position in the global generic drug industry and commands a significant presence in the specialty neurology market. Mr. Fletcher served as Vice President, Sales and Marketing of the Pennsylvania based Lemmon Company (1980 to 1983) and then as President (1983-1985) following the company's acquisition by Teva and WR Grace. Prior to 1980, Mr. Fletcher was Business Development Manager and International Marketing Manager of Synthelabo, a pharmaceutical subsidiary of L'Oreal in Paris. From 1970 to 1977 he served in various international sales and marketing positions for Hoffman-LaRoche. Mr. Fletcher graduated in International Marketing from Woolwich Polytechnic, London (now Greenwich University) in 1969. He serves as a Board Member for several Teva subsidiary companies in North America and Europe, and is a Director of Sportwall International Inc., a growth company in the interactive fitness industry. Paul E. Freiman, President and CEO, said, "Bill Fletcher brings extensive pharmaceutical and neurology experience to our company, and he will be a key asset as we drive our Phase III Viprinex(TM) and XERECEPT(R) programs forward. His distinguished leadership, which helped transform Teva into a major force, is invaluable as NTI continues to make its mark in important therapeutic areas." About Neurobiological Technologies, Inc. NTI is a biotechnology company engaged in the business of acquiring and developing central nervous system related drug candidates. The Company is focused on therapies for neurological conditions that occur in connection with ischemic stroke and brain cancer. The Company's strategy is to in-license and develop later-stage drug candidates that target major medical needs and that can be rapidly commercialized. NTI's experienced management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy. Forward-Looking Statements Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our need for additional capital, risks relating to the regulatory approval and commercialization of Viprinex, the inherent risk of failure in developing product candidates based on new technologies, the risks associated changes in our management team and other risks detailed from time to time in our Annual Report of Form 10-K and other filings with the Securities and Exchange Commission. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. We undertake no obligation to update these forward-looking statements. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Paul E. Freiman, President and CEO of Neurobiological Technologies, Inc., +1-510-595-6000 Web site: http://www.ntii.com/

Copyright